My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

The Cigna Group (CI) — RQD Stock Rating Cockpit

$273.03 -4.32% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $270.39

The Cigna Group (CI) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $71.94B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, The Cigna Group (NYSE: CI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $273.03 (-4.32% 1D, market cap $71.94B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CI ranks #435 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CI compare to ELV and HUM in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), CI carries a Roarable D- (39/100 RQD), trailing P/E of 13.2x, gross margin of 21.8%, and ROIC of 8.8%. By comparison, ELV (Elevance Health Inc.) holds a C grade (64/100 RQD, P/E 16.1x, ROIC 8.7%, cap $84.30B) and HUM (Humana Inc.) posts a C- grade (59/100 RQD, P/E 42.2x, ROIC 8.3%, cap $45.65B). Among the 5-stock peer group, CI leads on earnings multiple (13.2x) while CI leads on capital efficiency (8.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CI?
▼

Per CI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739940), The Cigna Group generated $274.90B in revenue (+11.2% YoY), $5.96B in net income, and -$2.77B in free cash flow against $157.92B in total assets and $52.22B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 CI TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $CI, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $CI R/R 2.2 : 1 • RQD 39/100 (D-)
$CI
Spot $273.03
1. GET IN (ENTRY)
$271.39–$274.40
2. HARD STOP (SUP)
$258.83 (-5.2%)
3. GET OUT (T1/T2)
$290.78 / $304.43
STOP-LOSS FLOOR (SUP $258.83): Hard stop sits 5.2% below spot to cap downside below key institutional support. If $CI closes a daily candle below $258.83, step aside.
PROFIT TARGETS (RES $290.78 / $304.43): Scale out 50% at T1 (+6.5%) and trail stop to breakeven for T2 (+11.5%).
Want this $CI sheet + Today's Top 3 Trades emailed free? Paper Trade $CI →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $CI Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $270.38 (-0.97%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D-
Cash (7)Whales (7)SEC (12)Macro (4)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-8.5% Base Target
$332 Bull$250 Base$195 Bear
📬 FREE CI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CI)Realized 20D OHLCV Swing Band: ±3.7%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY CI SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (31% of score)

Altman Z-Score 2.70 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (+0.80% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (30.9) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$302.07+0.4% Next Q
Q2 (-2Q)
44
Grade D$303.14-2% Next Q
Q3 (-1Q)
42
Grade D$297.15-8.1% Next Q
Current
39
Grade D-$273.03-7.6% Hist 90D α
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CI currently carries a cautious 39/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($289.71) and Max Pain ($286.68) forces dealer call-delta covering toward $332.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMOVERSOLD (<32)
30.930 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.70>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE26% OF RANGE
L: $258$273.03H: $316
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on CI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

8.8% ROIC with 21.8% gross margin and -3.51% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 2.70 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

16/40 institutional & smart-money positioning score with 4/20 macro alignment.

Bull Case: Why Buyers Like CI
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CI)

  • ✓Walkthrough of CI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.78%📐 HORIZONTAL RANGE
2026-11-22O $285.4H $285.4L $273.0C $273.0VOL 3.65M
$320.0$304.5$289.0$273.5$258.0RES $320.2SUP $262.6$273.02026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE NO MOAT (COST > RETURN) (ROIC 8.8% vs WACC 6.8%)

CI Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $372.53 vs Spot $273.03
SIGNIFICANTLY UNDERVALUED (+26.7%)
Undervalued Zone (< $317) Fair Value Corridor ($317–$428) Overvalued (> $428)
$273
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own CI Growth & WACC Assumptions

YOUR DCF TARGET
$505.11
5-Yr Annual FCF Growth Rate: 8.8%
Discount Rate (WACC Hurdle): 6.8%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +26.7% vs $273.03 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
4.5%/yr Implied 5Y Growth

vs. +11.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CI)

Health Care Rank #435 of 1015 ⚔️ ELV vs CI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CI vs. ELV, HUM, NTRA, CNC)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, The Cigna Group (CI) ranks #435 by composite RQD confidence (39/100, grade D-) and #28 by equity capitalization ($71.94B). Within this direct 5-issuer industry benchmark cohort, CI leads on earnings valuation at 13.2x trailing P/E, while CI leads on capital efficiency and profitability with 8.8% ROIC and 21.8% gross margin. ELV currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with CI at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CI ACTIVE
The Cigna Group
D- 39/100 13.2x 21.8% 8.8% -4.32% $71.94B Benchmark Subject
ELV
Elevance Health Inc.
C 64/100 16.1x 89.4% 8.7% -2.66% $84.30B /elv-vs-ci →
HUM
Humana Inc.
C- 59/100 42.2x — 8.3% -1.47% $45.65B /hum-vs-ci →
NTRA
Natera Inc.
C- 59/100 — — -4.9% +0.14% $42.04B /ntra-vs-ci →
CNC
Centene Corporation
D+ 57/100 — 8.1% -31.0% -2.74% $32.48B /cnc-vs-ci →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001739940 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), The Cigna Group (CI) reported GAAP revenue of $274.90B (+11.2% vs. FY2024 revenue of $247.12B , and +40.8% cumulative change since FY2023) , GAAP net income of $5.96B, operating cash flow of $9.60B, and free cash flow of -$2.77B (-265.6% YoY). On the balance sheet, CI closed FY2025 with $157.92B in total assets against $52.22B in total debt (Altman Z-Score: 2.70, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $274.90B $5.96B $9.60B -$2.77B $157.92B $52.22B
FY2024 (FY) 2024-12-31 $247.12B $3.43B $10.36B -$757.4M $155.88B $51.59B
FY2023 (FY) 2023-12-31 $195.26B $5.16B $11.81B $3.03B $234.32B $54.83B

3. CI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, The Cigna Group (NYSE: CI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $273.03 (-4.32% 1D, market cap $71.94B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CI ranks #435 in composite RQD confidence.

How does CI compare to ELV and HUM in the Health Care sector?

Within the Health Care sector (Medical Specialities), CI carries a Roarable D- (39/100 RQD), trailing P/E of 13.2x, gross margin of 21.8%, and ROIC of 8.8%. By comparison, ELV (Elevance Health Inc.) holds a C grade (64/100 RQD, P/E 16.1x, ROIC 8.7%, cap $84.30B) and HUM (Humana Inc.) posts a C- grade (59/100 RQD, P/E 42.2x, ROIC 8.3%, cap $45.65B). Among the 5-stock peer group, CI leads on earnings multiple (13.2x) while CI leads on capital efficiency (8.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CI?

Per CI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739940), The Cigna Group generated $274.90B in revenue (+11.2% YoY), $5.96B in net income, and -$2.77B in free cash flow against $157.92B in total assets and $52.22B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CI trading relative to its 50-day, 200-day, and 52-week technical levels?

CI last traded at $273.03 (-4.32% on volume of 3,650,601 shares), positioning the stock -5.76% below its 50-day simple moving average ($289.71) and -3.60% below its 200-day simple moving average ($283.24). Across its 52-week range of $257.85 to $316.27, CI sits at the 26.0% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±3.7% ($262.93 to $283.13).

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CI — The Cigna Group: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

The Cigna Group (CI) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $273.03 (-4.32% 1D, market capitalization $71.94B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of 8.8%, gross margin of 21.8%, operating margin of 3.3%, and free cash flow yield of -3.51%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (12/20): Incorporates a 1.12x equity beta, Altman Z-Score of 2.70, Piotroski F-Score of 5/9, and Debt/Equity of 1.17x.

2. Business Model, Unit Margins & SEC Financial Trajectory

And market profile, The Cigna Group is a NYSE-listed issuer in the Health Care sector, Medical Specialities industry. The source data reports revenue of $274.90B for FY 2025 but does not describe its products, customers, or revenue model. — for the specific revenue mix and customer segments.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), The Cigna Group (CI) reported $274.90B in annual revenue (up from $247.12B in FY2024, +11.2% YoY) and $5.96B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($195.26B revenue, $5.16B net income) through FY2025, CI scaled operating cash flow to $9.60B and free cash flow to -$2.77B, backed by $157.92B in total assets against $52.22B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.51% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $257.85 – $316.27 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 13.2x trailing P/E and 6.1x EV/EBITDA against 3.3% operating margins and a 1.12x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Per the news feed, one headline compares CI with CVS Health, which suggests peer relevance, but no upstream or downstream dependencies, sector correlations, or bottlenecks are documented in the source data.

  • Key Question #1: Can CI sustain or expand its 3.3% operating margin and 8.8% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $274.90B and free cash flow of -$2.77B, how will capital allocation balance growth reinvestment against $52.22B in total debt?
  • Key Question #3: How sensitive is CI's 12.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.12x)?

CI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for The Cigna Group (CI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CI Bull vs. Bear Conversation Board — What's Your Call at $273.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $375.77 (+26.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 16 of 20 in the Roarable RQD rating, and the forward P/E of 12.3 sits below th

Long CI at $298.23 targeting $375.77. Institutional accumulation and options positioning score 16 of 20 in the Roarable RQD rating, and the forward P/E of 12.3 sits below the trailing P/E of 13.2.. Institutional whale score is 16/20 and the risk/reward vs. the $255.53 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on 13.2x trailing P/E, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (21.8%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $244.55 (-18.0%)
Spot @ $298.23

Free cash flow was negative in FY 2025 and FY 2024, producing a -3.51% FCF yield that drags the Fundamental Cash Engine pillar to 7 of

Sitting on the sidelines or leaning short CI above $298.23. Free cash flow was negative in FY 2025 and FY 2024, producing a -3.51% FCF yield that drags the Fundamental Cash Engine pillar to 7 of 20.. Until Fundamental Cash Engine (7/20) and FCF yield (-3.51%) inflect higher, upside is capped near $316.27.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE